ENG

ENG简体中文日本語한국어

  • Shaun GAO

    Equity Partner / Shanghai

  • Tel +86-21-6061-3666

    Email shaungao@zhonglun.com

  • Practices

    Private Equity & Investment Funds, Hong Kong & Overseas Capital Markets, Cross-border Investment/M&A

  • Industries

    Telecom & Information, Intelligence Technology & Application, Pharmaceuticals & Life Sciences

CV

Shaun GAO

Shaun specializes in private equity and venture capital, cross-border mergers and acquisitions, corporate restructuring and offshore capital markets. Since 2005, Shaun worked in the Shanghai Office of two US based international law firms for more than ten years. His expertise spans across life sciences and healthcare, IT and telecoms, advertising and broadcasting, clean and renewable energy, education, new media, retailing and franchising, and traditional manufacturing sectors.

Notably, Shaun is one of the pioneering practitioners in PE/VC investment and financing in life sciences and healthcare sector. He led the design of multi-jurisdiction holding structure. Shaun's portfolio encompasses a number of eye-catching deals, clients including Innovent, CStone, Hua Medicine, I-Mab, Ocumension, Everest Medicines, GraCell, Transcenta, Abbisko, Genesis MedTech, Zylox-Tonbridge, Edge Medical, InSilico, New Horizen, etc.

Representative Matters

  • Advised Ocumension on its incubation and inception, each round of equity financing, restructuring, and initial public offering on the Main Board of the Stock Exchange of Hong Kong Limited 

  • Advised Everest Medicines on its incubation and inception, each round of equity financing (including its USD 310 million Series C financing, which was the largest single round financing in Zhong Lun's bio-tech practice), merger and restructuring, and initial public offering on the Main Board of the Stock Exchange of Hong Kong Limited 

  • Advised GraCell on its incubation and inception, multiple rounds of equity financing, red-chip restructuring, and initial public offering on Nasdaq

  • Advised C-Mab on its incubation and inception, each round of equity financing, and trade sale

  • Advised Cyclone on its multiple rounds of equity financing, including the latest USD 150 million Series C financing, which represents the largest single round financing in PRC RPA sector to date

  • Advised Lianlian Pay on its restructuring and multiple rounds of equity financing

Honors and Awards

For Individual

Highly Regarded - Private Equity, IFLR1000, 2023

Rising Star Partner - Private Equity and Merger and Acquisition, IFLR1000, 2022-2023

Publications

"When the only certainty is uncertainty - An analysis on VC investment structure and terms design on pharmaceuticals sector", Zhong Lun Research Center, 2018

Related

  • Bar Admissions/Professional Qualifications

    PRC Bar, 2006

  • Education

    LL.M., University of Sheffield
    LL.B., East China University of Political Science and Law

  • Professional Experience

    Equity partner, Zhong Lun Law Firm
    Senior Counsel, Katten Muchin Rosenman LLP
    Legal Consultant, Troutman Pepper Hamilton Sanders LLP

  • Languages

    Chinese
    English